← Back to Search

Photo-activation of Riboflavin

Crosslinking for Corneal Neovascularization

Price Vision Group, Indianapolis, IN
30 minute photoactivation of riboflavin 0.1% +1 morePhase 2 & 3RecruitingLed by Francis W Price, Jr., MDResearch Sponsored by Price Vision Group

Study Summary

This trial will test if a light-activated vitamin can safely and effectively treat an eye condition that causes new blood vessels to grow.

Eligible Conditions
  • Corneal Neovascularization

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
corneal neovascularization as a proportion of the total corneal area

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: 10 minute photoactivationActive Control1 Intervention
photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes
Group II: 30 minute photoactivationActive Control1 Intervention
photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes

Find a Location

Who is running the clinical trial?

Price Vision GroupLead Sponsor
10 Previous Clinical Trials
1,521 Total Patients Enrolled
Cornea Research Foundation of AmericaOTHER
7 Previous Clinical Trials
2,957 Total Patients Enrolled
Francis W Price, Jr., MDPrincipal InvestigatorPrice Vision Group
5 Previous Clinical Trials
3,386 Total Patients Enrolled

Media Library

10 minute photoactivation of riboflavin 0.1% (Photo-activation of Riboflavin) Clinical Trial Eligibility Overview. Trial Name: NCT04787471 — Phase 2 & 3
Corneal Neovascularization Research Study Groups: 10 minute photoactivation, 30 minute photoactivation
Corneal Neovascularization Clinical Trial 2023: 10 minute photoactivation of riboflavin 0.1% Highlights & Side Effects. Trial Name: NCT04787471 — Phase 2 & 3
10 minute photoactivation of riboflavin 0.1% (Photo-activation of Riboflavin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04787471 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does 30 minute photoactivation therapy usually target?

"30 minute photoactivation can be used for a variety of conditions, such as vitamin deficiency, joint pain, and vitamin supplementation."

Answered by AI

Are there any other research studies that use 30 minute photoactivation?

"As of now, there are 20 trials being run studying 30 minute photoactivation. 11 of those active studies are in Phase 3. While the majority of studies for 30 minute photoactivation are based in San Francisco, California, there are 47 locations running trials for this treatment."

Answered by AI

How many participants will be taking part in this experiment?

"That is correct. The listing on clinicaltrials.gov makes it clear that this study is still recruiting patients. The trial was first announced on May 3rd, 2021 and was last updated on July 27th, 2022. Currently, the research team is looking for 62 individuals from a single site."

Answered by AI

Are new participants being taken in for this experiment?

"That is correct, the listing on clinicaltrials.gov currently says that this study is open for recruitment. This specific trial was first announced on May 3rd, 2021 and was last updated on July 27th, 2022. They are 62 patients needed in total from 1 site."

Answered by AI
Recent research and studies
~21 spots leftby Apr 2025